Rashes are a common side effect of some prostate cancer treatments. Rarely, they may be caused by cancer cells.

The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Drug rashes can be an unwanted side effect of many medications. Learn which medications can cause these skin reactions.

Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...

Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...

Adults with chronic spontaneous urticaria experienced greater mortality, probably due to increased risks for comorbidities, ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic spontaneous ...

The following is a summary of “Patient and physician perspectives on disease burden in chronic spontaneous urticaria,” published in the March 2025 issue of Annals of Allergy, Asthma & Immunology by ...

When your skin is red, itchy, and irritated, it could be a rash or it might be hives. We spoke with experts to learn how to tell the difference and the best ways to manage them.

Morgan Stanley has initiated Celldex Therapeutics (NASDAQ:CLDX) at overweight saying that barzolvolimab (barzol), its asset for chronic urticaria (CU), is poised to become a major revenue ...